ClinicalTrials.gg
TerminatedNCT02386735RECUTUpdated Mar 12, 2025

Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD

An interventional study of Placebo and Prednisone in Pulmonary Disease, Chronic Obstructive, Adverse Effect of Glucocorticoids and Synthetic Analogues and Disease Exacerbation, sponsored by Prof. Dr. Jörg Leuppi. Terminated at 1 site in Switzerland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Prof. Dr. Jörg Leuppi · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Low recruitment rate, motivation and engagement of participating GPs unfortunately declined over time, as well as the financial resources.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.

Enrollment
28th of 77
133 · median 74
Started
2015
with 4 others
No phase
46 of 99
8 open now
Registered
43rd of 99
by date

Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 28th largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2015, is one of 46 with no phase, and was the 43rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, or all of them as a file.
02

Study summary

Background

Chronic obstructive pulmonary disease (COPD) is a major public health issue with no curative treatment. In Switzerland estimated 5-7% of the total population are suffering from this chronic disease. According to current guidelines corticosteroids are part of treatment of acute exacerbations in COPD patients. Several studies suggest that corticosteroids accelerate the recovery of forced expiratory volume in 1 second (FEV1), decrease duration of hospitalization, reduce treatment failure rate and improve clinical outcome. The additional therapeutic benefit on FEV1-recovery tough seems only to last for three to five days. The investigators recently published a hospital-based study showing that in patients presenting to emergency departments with acute exacerbation of COPD, a short five day treatment with systemic steroids was not inferior to a conventional 14 day treatment with regard to re-exacerbation. Cumulative corticosteroid dose could be reduced in this trial. To the investigators knowledge no data is available about the minimal necessary corticosteroid dose in an outpatient treatment setting so far.

Aim

The primary aim of this study is to investigate in an outpatient setting, whether a three day treatment with orally administered systemic corticosteroids is non-inferior to a five day treatment in acute exacerbation of COPD and if total glucocorticoid exposure can be reduced by shorter therapy.

Hypothesis

The investigators postulate, that in an outpatient setting, where generally less severe exacerbations are being treated, a three day treatment duration of systemic corticosteroids should be non-inferior to a five day treatment duration with regard to treatment benefits but decrease cumulative corticosteroid exposure.

Design and Setting

This study is going to be performed as a prospective, randomized, double-blind, placebo-controlled, non-inferiority trial in an outpatient setting. Randomization will be performed as block randomization with a 1:1 allocation. The investigators are going to recruit GPs in northwestern and central Switzerland.

Methods

The investigators are going to include patients presenting to GP's with acute exacerbation of COPD. When matching the investigators eligibility criteria and written informed consent is given, patients included in the study are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for either five days (conventional arm) or three days (interventional arm) followed by two days of placebo for the interventional group. Pre-randomized, identically looking, numbered blisters are given to all patients included in the study. Antibiotic treatment (Amoxicillin/Clavulanic acid, 625mg 3/d, for ten days) is given to all patients with a CRP ≥50mg/l, COPD and known diagnosis of bronchiectasis, as well as patients presenting with all three of the following symptoms: change of baseline dyspnea, change of sputum quantity and sputum purulence. Further initial treatment and steroid treatment after inclusion is determined and documented by the GP. Patients will undergo follow-up visits at day three and seven by their GP as well as follow-up phone calls executed by the study center at day 30, 90 and 180.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
  • Adverse Effect of Glucocorticoids and Synthetic Analogues
  • Disease Exacerbation

Keywords

  • Corticosteroid treatment
  • COPD
  • Primary Health Care
  • Randomized controlled trial
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Age ≥40 years
  • History of ≥10 pack-years of smoking (past or present smokers)
  • Airway obstruction, defined as /FVC≤70%
  • Current acute exacerbation of by clinical criteria, defined by the presence of at least two of the following:

    • Change of baseline dyspnea
    • Change of cough
    • Change of sputum quantity or purulence

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of asthma
  • Initial necessity of hospitalization
  • Women who are pregnant or breast feeding
  • Premenopausal women with insufficient and anamnestic risk for pregnancy
  • Severe coexisting disease with \<6 months
  • Diagnosis of tuberculosis
  • Known severe or immunosuppression after solid organ or stem cell transplantation
  • Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study involving an drug
  • Previous enrolment into the current study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Investigational treatment

    Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.

    Drug: Placebo

  • Active comparator
    Standard treatment

    Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.

    Drug: Prednisone

Interventions

  • DrugPlacebo

    Three days prednisone 40mg, two days placebo

  • Five days prednisone 40mg.

06

What researchers measure

Primary outcomes

  1. Time to next exacerbation

    Time frame: Six month follow-up period after index exacerbation.

Secondary outcomes

  1. Cumulative glucocorticoid dose

    Time frame: Six month follow-up period after index exacerbation.

  2. Glucocorticoid side effects and complications

    Time frame: Six month follow-up period after index exacerbation.

  3. Change in FEV1

    Time frame: 7 days follow-up period after index exacerbation.

  4. Hospitalization rate during index exacerbation

    Time frame: Six month follow-up period after index exacerbation.

  5. Overall mortality

    Time frame: Six month follow-up period after index exacerbation.

07

Study locations

1 site
  • Kantonsspital Baselland
    Liestal, BL 4410, Switzerland
08

References and documents

Publications

  • Leuppi JD, Miedinger D, Chhajed PN, Buess C, Schafroth S, Bucher HC, Tamm M. Quality of spirometry in primary care for case finding of airway obstruction in smokers. Respiration. 2010;79(6):469-74. doi: 10.1159/000243162. Epub 2009 Sep 26. PubMed 19786731 ↗
  • Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847-52. doi: 10.1136/thorax.57.10.847. PubMed 12324669 ↗
  • Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007 Jun;101(6):1305-12. doi: 10.1016/j.rmed.2006.10.012. Epub 2006 Nov 16. PubMed 17112715 ↗
  • Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000 Jul 27;343(4):269-80. doi: 10.1056/NEJM200007273430407. No abstract available. PubMed 10911010 ↗
  • Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax. 2006 Mar;61(3):250-8. doi: 10.1136/thx.2005.041822. PubMed 16517585 ↗
  • Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. No abstract available. PubMed 19038881 ↗
  • Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010 Apr;15(3):536-42. doi: 10.1111/j.1440-1843.2010.01722.x. PubMed 20415983 ↗
  • Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Muller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023. PubMed 23695200 ↗
  • Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980 Jun;92(6):753-8. doi: 10.7326/0003-4819-92-6-753. PubMed 6770731 ↗
  • Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest. 1989 Mar;95(3):563-7. doi: 10.1378/chest.95.3.563. PubMed 2920584 ↗
  • Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med. 1996 Mar;14(2):139-43. doi: 10.1016/S0735-6757(96)90120-5. PubMed 8924134 ↗
  • Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):407-12. doi: 10.1164/ajrccm.154.2.8756814. PubMed 8756814 ↗
  • Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003 Jun 26;348(26):2618-25. doi: 10.1056/NEJMoa023161. PubMed 12826636 ↗
  • Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999 Jun 24;340(25):1941-7. doi: 10.1056/NEJM199906243402502. PubMed 10379017 ↗
  • Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60. doi: 10.1016/s0140-6736(98)11326-0. PubMed 10465169 ↗
  • Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003 Aug;124(2):459-67. doi: 10.1378/chest.124.2.459. PubMed 12907529 ↗
  • Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med. 1999 Mar;93(3):173-9. doi: 10.1016/s0954-6111(99)90004-5. PubMed 10464874 ↗
  • Walsh LJ, Lewis SA, Wong CA, Cooper S, Oborne J, Cawte SA, Harrison T, Green DJ, Pringle M, Hubbard R, Tattersfield AE. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med. 2002 Sep 1;166(5):691-5. doi: 10.1164/rccm.2110047. PubMed 12204867 ↗
  • Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994 Jul;150(1):11-6. doi: 10.1164/ajrccm.150.1.8025735. PubMed 8025735 ↗
  • Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8. PubMed 25196117 ↗
  • Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007 Sep 1;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4. Erratum In: Lancet. 2012 Sep 1;380(9844):806. PubMed 17765523 ↗
  • Jochmann A, Scherr A, Jochmann DC, Miedinger D, Torok SS, Chhajed PN, Tamm M, Leuppi JD. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567. eCollection 2012. PubMed 22481636 ↗
  • Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204. doi: 10.7326/0003-4819-106-2-196. PubMed 3492164 ↗
  • Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398S-401S. doi: 10.1378/chest.117.5_suppl_2.398s. PubMed 10843984 ↗
  • Urwyler P, Boesing M, Abig K, Cattaneo M, Dieterle T, Zeller A, Bachler H, Markun S, Senn O, Merlo C, Essig S, Ullmer E, Rutishauser J, Schuurmans MM, Leuppi JD. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial). Trials. 2019 Dec 16;20(1):727. doi: 10.1186/s13063-019-3856-8. PubMed 31842993 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Jul 2024 and a completion of Jul 2024. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2015
First posted
Mar 12, 2015
Start
Mar 2015
Primary completionActual
Jul 31, 2024
CompletionActual
Jul 31, 2024
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02386735
Lead sponsor
Prof. Dr. Jörg Leuppi
Collaborators
Institut für Hausarztmedizin Basel, Kantonsspital Baselland Bruderholz
Responsible party
Prof. Dr. Jörg Leuppi (Prof. Dr. med., Cantonal Hosptal, Baselland) — Sponsor-investigator
First posted
Mar 12, 2015
Start date
Mar 2015
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024
Last update
Mar 12, 2025

Study contacts

Joerg D. Leuppi, Prof.
principal investigator · Kantonsspital Basleland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion